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Abstract
West Nile virus (WNV) replicates in a wide variety of avian species, which act as amplification 
hosts. In particular, WNV generates high titers and elicits severe pathology in American crows 
(AMCRs; Corvus brachyrhynchos), a species that has been used as a sentinel for WNV 
transmission. Although the specific cellular targets of WNV replication in AMCRs are not well 
defined, preliminary evidence suggests that leukocytes may be an important target of early 
replication. Therefore, development of a protocol for ex vivo culture of AMCR leukocytes as a 
model for assessing differential avian host susceptibility is described herein. WNV growth in these 
cultures mirrored in vivo viremia profiles. These data indicate that ex vivo leukocyte cultures can 
be used for preliminary pathological assessment of novel WNV strains and potentially of other 
flaviviruses that use avian reservoir hosts.
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West Nile virus (WNV) is the most common cause of neuroinvasive arboviral disease in the 
United States, resulting in over 39,000 cases of human illness and over 1500 deaths since its 
initial identification in New York City in 1999 (Reimann et al., 2008; Lindsey et al., 2013; 
CDC, 2014). WNV belongs to the genus Flavivirus within the family Flaviviridae. WNV is 
maintained in an enzootic cycle through transmission between avian reservoir hosts and 
mosquito vectors (Reisen, 2013). Mammals, particularly humans and horses, are susceptible 
to WNV infection and disease, but do not develop sufficient viremia to infect mosquitoes 
and are considered to be dead-end hosts (Komar, 2003; Petersen et al., 2013).
Avian mortality, particularly in corvid species, has been a hallmark of WNV transmission in 
North America (Bernard et al., 2001; Komar et al., 2003; Nemeth et al., 2007). American 
crows (AMCRs; Corvus brachyrhynchos) are highly susceptible to WNV, with a high 
mortality rate, and have been used as a sentinel species (Eidson et al., 2005; Nemeth et al., 
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2007). A single mutation at amino acid position 249 in the NS3 helicase gene of WNV has 
been shown to modulate virulence and pathogenicity in AMCRs and other avian species 
(Brault et al., 2007; Langevin et al., 2014). North American strains of WNV, such as NY99, 
contain a proline residue at this position and are highly virulent in AMCRs. In contrast, 
strains such as KN3829, which was isolated in Kenya and contains a threonine residue at 
NS3-249, elicit limited viremia and mortality in AMCRs (Brault et al., 2004). In the NY99 
genetic backbone, an NS3-P249T mutation was found to reduce both mortality rates and 
magnitude of viremia in AMCRs. Conversely, an NS3-T249P mutation in the KN3829 virus 
increased viremia and mortality to levels comparable to those of NY99 (Brault et al., 2007).
Both NY99 and KN3829 belong to WNV lineage 1a, in which the ancestral residue at 
NS3-249 is a threonine. The NS3-249 residue is under positive selective pressure, and has 
evolved independently to a proline residue multiple times in lineages 1a and 2 (Brault et al., 
2007; Papa et al., 2011). Strains from other lineages contain alternative residues at this 
position, with varying effects on WNV pathogenesis in birds when introduced into the 
NY99 genetic background (Langevin et al., 2014). This suggests that the presence of a 
proline residue at this site may be advantageous for the virus, likely due to its effect on 
replication in birds and subsequent increased infectivity for mosquitoes imbibing high-
titered blood meals.
Pathologic assessment of WNV in avian hosts is time-consuming and labor-intensive, 
requires periodic trapping of wild birds, can result in variable outcomes due to the presence 
of adventitious infectious agents in outbred avian populations, and is dependent on 
specialized facilities for housing of birds at biosafety level 3 and approvals for animal use 
(Pérez-Ramírez et al., 2014). As such, it would be advantageous to have a relatively non-
invasive, reproducible model system for assessing the potential avian host competence of 
novel strains. The replication potential of WNV in avian tissues is not well understood, but 
WNV replicates in mammalian leukocytes (Garcia-Tapia et al., 2006; Rios et al., 2006; Bai 
et al., 2010), and preliminary data (not shown) suggested that avian leukocytes may also be 
targets. Peripheral blood mononuclear cells (PBMCs) can be isolated easily and 
noninvasively. Therefore, the goal of this study was to determine whether the in vivo 
phenotypes of NY99, KN3829, and NS3-249 point mutants could be recapitulated in an ex 
vivo AMCR PBMC culture model.
After hatch-year AMCRs were cannon-netted in 2013 and 2014 under US Fish and Wildlife 
Services and Colorado Parks and Wildlife permits at two sites in Bellvue, Colorado (40° 38′ 
51″, 105° 11′ 15″ W and 40° 37′ 35″ N, 105° 10′ 32″ W). AMCRs were banded, bled to 
assay for pre-existing neutralizing antibodies against WNV and St. Louis encephalitis virus, 
and housed at Colorado State University in a large open flight room containing 25-150 
crows. Crows were fed dry dog food ad libitum (Brault et al., 2004; Langevin et al., 2014). 
Animal experiments were approved by the Institutional Animal Care and Use Committee of 
Colorado State University (Protocol #12-3871A).
Whole blood (0.5 ml) was collected from each AMCR by jugular venipuncture using a 27-
gauge syringe and expelled into lithium heparin tubes (BD Vacutainer). Blood from 6 birds 
was pooled for a total of 3 ml per tube. Pooled blood was diluted with 8 ml of Dulbecco’s 
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phosphate-buffered saline (DPBS) and layered onto 3 ml of Histopaque-1077 (Sigma-
Aldrich) in a 15-ml conical tube. This column was centrifuged at 400×g for 30 minutes with 
no brake. The opaque interface was removed and washed three times in DPBS with 
centrifugation at 250×g for 10 minutes. The cell pellet was resuspended in growth medium 
[RPMI containing 10% fetal bovine serum, 100 U/ml penicillin/streptomycin, and 1 μg/ml 
Fungizone (Life Technologies)], counted with a hemocytometer, and seeded in 12-well 
plates at a density of 1.5×106 cells/well. The average yield from 3 ml blood was 2.70×107 
cells, or approximately 18 wells.
KN3829 virus stocks were passaged once in Vero cells (Kinney et al., 2006). NY99 wild-
type and mutant viral stocks were derived from infectious clones as previously described 
(Kinney et al., 2006). Briefly, the 5′ and 3′ plasmids were digested with NgoMIV, ligated, 
and linearized with XbaI (New England Biolabs) before in vitro transcription with the 
Ampliscribe High-Yield T7 Transcription kit (Epicentre Biotechnologies). Viral RNA was 
transfected into BHK-21 cells by electroporation (Kinney et al., 2006).
PBMCs were incubated with viral stock for 1 hour at 37°C in a total volume of 1.5 ml 
before being centrifuged at approximately 1500×g and resuspended in fresh growth medium. 
Supernatant (1.5 ml) was saved as time point 0, and stored at −70°C until titration by plaque 
assay. One third of the well volume (0.5 ml) was sampled every 24 hours. Cells were 
centrifuged as above, supernatant was collected, and cells were resuspended in 0.5 ml 
growth medium and returned to the well.
In preliminary experiments, PBMCs were inoculated with wild-type NY99. Cell counts 
revealed steady mortality of PBMCs over the course of the experiment, regardless of 
infection (Figure 1A). Viral titers decreased by approximately 2-3 log10 in the first 24 hours 
post-inoculation, presumably reflecting removal of the initial inoculum and the eclipse phase 
of viral growth. At subsequent time points, titers of NY99 remained approximately constant 
when infection was performed at a multiplicity of infection (MOI) of 10, despite daily 
removal and replacement of growth medium. In contrast, infection with lower MOI resulted 
in decreases in viral titer, reaching the limit of detection on or before 6 days post-infection 
(dpi) (Figure 1B). Therefore, subsequent experiments were performed for six days at an 
MOI of 10.
Viral growth kinetics were variable between experiments, likely because the source of cells 
was wild-caught birds of unknown health status. In a number of experiments conducted with 
NY99, viral titers sometimes plateaued after the initial decline, remaining at approximately 
4-5 log10 pfu/ml after 2-4 dpi (e.g. Experiment 7, Figure 2A). Alternatively, titers sometimes 
increased to 6-7 log10 pfu/ml (e.g. Experiment 6, Figure 2A). In contrast, mean titers of 
KN3829 and the NY99 NS3-P249T mutant virus, both of which are less pathogenic for 
AMCRs, either decreased to undetectable levels (Experiment 7), plateaued (Experiment 6; 
NS3-P249T), or increased slightly late in infection (Experiment 6; KN3829) (Figure 2B). 
Importantly, although the titers attained in each specific experiment varied, titers of KN3829 
and the NS3-P249T mutant were consistently lower than those of NY99 assayed in the same 
experiment. This effect cannot be attributed to a difference in virion stability, because NY99 
and KN3829 decay at equivalent rates in the absence of cells (Kinney et al., 2006).
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Because wild-type NY99 was included as a positive control in every experiment, the 
replication potential of each strain in PBMCs could be expressed as a ratio. Specifically, the 
log-transformed titer attained by KN3829 or NY99-NS3-P249T at 6 dpi was divided by the 
log-transformed titer attained by NY99 in the same experiment. For samples in which virus 
was not detected, the titer was assumed conservatively to be the limit of detection (0.7 log10 
pfu/ml). The titer ratio was 0.19 and 0.48 in two experiments using NY99-NS3-P249T and 
ranged from 0.15 to 0.78 in four experiments using KN3829.
The highest value of the ratio for both KN3829 and NY99-NS3-P249T was attained in a 
single experiment (Experiment 6; Figure 2C), in which the variability among technical 
replicates was extremely high. Because reversion and compensatory mutations have been 
identified in in vivo infection experiments with NS3-249 mutants (Langevin et al., 2014), 
RNA was extracted from the supernatant samples from the last day with detectable virus in 
this experiment (5 dpi for NY99 NS3-P249T replicate #2; 6 dpi for all others). RT-PCR was 
performed with primers WNV5032F (GGAACATCAGGCTCACCAATAGTGG) and 
WNV5497R (CTTTGTGGAAATGTAACCTCTTGCTGC), and the resulting PCR product 
was sequenced. An NS3-T249A mutation was observed in two of three replicates of 
KN3829 (replicates #1 and 2, Figure 2C), correlating with increased PBMC replication 
compared to the third replicate, which retained the wild-type KN3829 sequence. No 
mutations were observed in the NY99 NS3-P249T samples; however, it is possible that the 
experimental variability among these samples was caused by mutation(s) in a region that 
was not sequenced.
In one experiment (Experiment 8; Figure 2), viral growth was assessed in Transwell plates 
containing a 0.4 μm membrane (Corning). Cells were mixed with virus in the upper well, 
and media was sampled from the lower well and replaced every 24 hours. This system 
allows for the removal of virus-containing medium without centrifugation of cells. In this 
system, titers of NY99 rose early in the experiment, peaking at 2 dpi, while titers of KN3829 
began to rise only after 3 dpi. Although the Transwell system was not assessed further in this 
study, it may provide a convenient alternative to the sampling methods used above, as it 
reduces the requirement for manipulation and potential for cell loss during centrifugation. 
However, the day 6 titer ratio described above would not be appropriate in the Transwell 
system, given that titers of KN3829 had increased to equal those of NY99 by this time point. 
The difference in titers was greatest at 2 dpi; however, the appropriate time point to use for 
such a ratio in the Transwell system would likely have to be determined empirically.
To assess the potential of the ex vivo PBMC culture assay to predict avian host competence, 
AMCR PBMCs were inoculated with a panel of NY99 NS3-249 mutants that have been 
shown to elicit a variety of viremia magnitudes and levels of mortality in AMCRs. Of these 
mutants, NS3-P249H and P249D exhibited virulence in AMCRs comparable to the wild-
type virus, while P249T elicited limited viremia and low mortality. The P249A and P249N 
viruses displayed intermediate in vivo viremia and mortality phenotypes (Langevin et al., 
2014).
As described above, titers of NS3-P249T in ex vivo PBMC culture decreased to undetectable 
levels by 5 dpi, while wild-type NY99 titers plateaued at approximately 4 log10 pfu/ml of 
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culture supernatant (Figure 3A). Growth profiles of P249H and P249N mutants were not 
distinguishable from wild-type at any time point. By 6 dpi, P249A and P249D mutants 
exhibited titers approximately 1-1.5 log10 pfu/ml supernatant lower than wild type (p < 0.05, 
Student’s t-test). It is intriguing that P249N and P249D mutants had opposing phenotypes ex 
vivo compared to their in vivo phenotypes. Viral RNA isolated from PBMC culture 
supernatants was sequenced as described above to verify the identity of these two strains and 
to assess the potential for genetic modulation at the NS3-249 loci. All sequencing reactions 
demonstrated the expected amino acid identity at the NS3-249 loci with no observed genetic 
mutations.
In order to quantify the degree to which the PBMC assay can predict in vivo phenotypes, the 
titers of the NY99 NS3-249 mutants, as well as the KN3829-T249P mutant, were 
normalized to the titer of NY99 in the same experiment, as described above. These titers 
were positively correlated with in vivo peak titers in AMCRs (R = 0.8726; p = 0.005; Figure 
3B) (Brault et al., 2007; Langevin et al., 2014).
Overall, these experiments demonstrate that WNV growth in ex vivo culture of AMCR 
PBMCs is capable of differentiating strains with medium-to-high pathogenicity in AMCRs 
from those with low pathogenicity. This method will be useful for the initial assessment of 
the potential avian virulence of novel WNV strains. It can likely be expanded to other avian 
species and used with related flaviviruses for which birds serve as reservoir hosts, such as 
St. Louis encephalitis and Japanese encephalitis viruses. Additionally, ex vivo culture of 
likely target cells will aid in molecular analysis of host factors and pathogen-associated 
molecular patterns (PAMPs) that could define the competence of reservoir species for WNV 
and other flaviviruses.
There are some caveats to the potential use of this ex vivo AMCR PBMC culture system for 
recapitulation of in vivo growth and virulence phenotypes. Inter-experiment variability is 
quite high (Figure 2), and it will be important to assess novel strains in comparison to 
control strains with known growth and pathogenicity phenotypes, such as NY99 and 
KN3829. The reasons for the variability in viral growth are unclear, but they may be related 
to the genetics and/or infection and immune status of the individual birds sampled in each 
experiment. It may be possible to reduce variability by limiting the animals bled for each 
experiment to a set of defined individuals whose PBMCs have been assessed previously for 
viability and viral replication potential. Alternatively, to reduce inter-experimental 
variability, attempts are underway to create immortalized cell lines derived from AMCR 
PBMCs.
High intra-experiment variability was also observed in one experiment. Sequencing revealed 
a point mutation at the NS3-249 site in KN3829 that correlated with differential replication 
capacity in this experiment. The possibility of mutation during growth in PBMCs should be 
taken into account during assessment of novel strains, particularly if high intra-experiment 
variability is observed.
Intermediate and high pathogenicity strains may not be reliably distinguishable in this 
system (Figure 3). It is not clear why the NS3-P249N and P249D mutants had different 
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phenotypes in ex vivo leukocyte culture than in vivo. This may be attributable to innate 
variability in both in vivo and ex vivo systems, or to differential replication of the two 
mutants in non-leukocyte cell types. It is also possible that there may be subtle differences in 
the replication of one or more mutants between in vivo and ex vivo leukocytes, depending on 
media conditions and differentiation status of the cells. If such differences are not uniform 
between WNV strains and mutants, they could cause the differences observed here. Further 
work will be necessary to address these questions.
The ex vivo system is clearly not a replacement for in vivo pathological assessment of viral 
strains. However, in general, it does recapitulate in vivo phenotypes and can be used as a 
tool to predict in vivo virulence and to help limit the number of avian hosts to be used in 
more invasive studies.
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(A) Cell death during PBMC culture and infection with WNV NY99 (MOI 0.5; experiment 
1). (B) Effect of MOI on viral replication in PBMC culture. Experiment 2 was conducted in 
single wells, while experiment 3 was conducted in triplicate (error bars depict standard 
deviation from the mean). The dashed line represents the limit of detection.
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Reproducibility of PBMC infection experiments. (A) WNV NY99 and (B) KN3829 and 
NY99-NS3-P249T were cultured in AMCR PBMCs isolated in multiple independent 
experiments. Numerical prefixes in the legend represent experiments; experiments with the 
same number in panels A and B were performed in parallel. The dashed line represents the 
limit of detection. Experiment 1 was conducted at MOI 0.5; all others were performed at 
MOI 10. Experiments 1 and 2 were conducted in single wells, while all others were 
conducted in triplicate (error bars represent standard deviation from the mean). Experiment 
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8 was conducted in Transwell plates. (C) Individual replicates of KN3829 and NY99 NS3-
P249T in experiment 6.
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(A) Growth of WNV NY99 NS3-249 mutants in AMCR PBMCs. NY99 wild-type (NS3-
P249) and NS3-P249T mutant data correspond to experiment 7 in Figure 2. The dashed line 
represents the limit of detection. Error bars represent standard deviation from the mean of 
three replicates. (B) Scatterplot comparing day 6 PBMC titers to peak in vivo titers in 
AMCRs. Legend is as in (A), with the addition of KN3829 (black circles) and KN3829-
T249P (open diamonds) (Brault et al., 2007; Langevin et al., 2014). R = 0.8726; p = 0.005.
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